A correlation was observed between reduced plasma levels of four specific EV-melanoma membrane-bound proteins (MCSP, MCAM, ERBB3 and LNGFR) and response to treatment involving combination BRAF/MEK inhibitors in patients with metastatic disease harbouring the BRAF V600E mutation [197]. This evidence concerns the gene BRAF and melanoma.